TARGETED THERAPY OF NSCLC WITH EGFR ACTIVATING MUTATIONS IMPROVES THE QUALITY OF LIFE OF PATIENTS

Abstract

Conversion of the incurable disease in the chronic form and improvement of the life quality parameters on the background of appearance of new drugs is of specific importance for patients with NSCLC with activating mutations. “ESMO thinks that treatment of patients with wide-spread and incurable cancer forms a greater share of the oncologists work… and for these patients the quality of life is of chief importance irrespective of its duration. Use of high-precision targeted anti- EGFR therapy allows considerably improving the quality of life of oncologic patients with non-small pulmonary carcinoma with activating mutations.

Keywords

• itk egfr
• pfs
• quality of life
• nsclc mut +
• afatinib